CORT108297

Phase 2Small molecule

VVA Office of Research and Development

CORT108297 is one of 3 small molecule programs targeting Mild Cognitive Impairment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Mild Cognitive ImpairmentRecruiting

Mild Cognitive ImpairmentPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Mild Cognitive Impairment

#DrugCompanyPhaseTrials

Ginkgo Biloba Extract

NNational Center for Complementary and Integrative Health (NCCIH)

Approved

1 2

Nicotinamide Riboside

UUniversity of Oklahoma

Phase 1

1 3

CORT108297

VVA Office of Research and Development

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Post-Traumatic Stress Disorder, PTSD

NCT04452500

Q1 2028

Phase 2Recruiting

Mild Cognitive Impairment

NCT04601038

Clinical

Trials by Indication[1]

Post-Traumatic Stress Disorder, PTSD1 trial

Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study)

Recruiting·VVA Office of Research and Development·Phase 2·NCT04452500·40 enrolled

Mild Cognitive Impairment1 trial

Phase II Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)

Recruiting·JJohns Hopkins University·Phase 2·NCT04601038·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CORT108297. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CORT108297 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CORT108297. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — VA Office of Research and Development company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: VVA Office of Research and Development

CORT108297

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Trials by Indication[1]

Post-Traumatic Stress Disorder, PTSD1 trial

Mild Cognitive Impairment1 trial

References

Drug Info

Quick Facts

Related News